The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London pre-open: Modest rise expected following FOMC statement

Thu, 01st May 2014 07:40

The City is set to edge higher early on, tracking gains in the US last night which came after the much anticipated statement from the Federal Reserve, which held steady on its policy course with a few breezily positive remarks leading to a positive finish Stateside. Sources predict the FTSE 100 will open around 10 points higher than yesterday's close of 6,780.03.As expected, the Federal Open Market Committee yesterday revealed it continued to taper its monthly asset purchases with another $10bn increment, despite data out earlier in the day showing near-stagnation in first-quarter gross domestic product growth. Meanwhile, activity in the Chinese manufacturing sector picked up a little in April, but came in slightly lower than analysts' expectations.The government's manufacturing purchasing managers' index (PMI) increased to 50.4 last month from 50.3 in March, according to the National Bureau of Statistics. The consensus forecast, however, was for a bigger rise to 50.5. Any figure above 50 denotes growth.Nevertheless, as analysts at Rabobank pointed out, the official PMI "still remains in far more optimistic territory than the HSBC/Markit measure (which captures more small firms)".In UK-listed company news, embattled government outsourcing group Serco announced late last night that it planned to raise around £170m to strengthen its balance sheet. Its year-to-date performance has been weaker than expected, with the company forced to warn on full-year profits on Monday and now said that adjusted operating profit in 2014 would be not less than £170m, down from guidance £220-250m just seven weeks ago. The group also received the resignation of its long-standing Chief Financial Officer (CFO) Andrew Jenner, who has been in the role since 2002. He will remain as CFO until a successor is appointed. This morning, fund manager Schroders reported record assets under management (AuM) in the first quarter, helped by nearly four billion pounds of net new business wins during the period. Chief Executive Michael Dobson said that "2014 has started well for Schroders" with £3.8bn of net inflows across multi-asset, equities and fixed income, taking AuM to an all-time high of £268bn as of March 31st.Drugs giant GlaxoSmithKline announced that the US Food and Drug Administration has approved its Incruse medication known as Ellipta as an anticholinergic used as long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The drug, which is administered via an inhaler, is expected to be launched in the US in the final quarter of this year. Engineering group Weir said trading in the last four months has been in line with expectations, helped by a strong performance in the oil and gas and power and industrial divisions, as it sticks to its full-year targets. The FTSE-100 group reiterated that that it expects good constant currency revenue and profit growth with margins broadly in line with 2013 levels, however reported results will be hurt by adverse foreign currency movements.Earnings fell 2.4% at BSkyB despite a rise in revenues as high levels of investment in connected television services continued.NR
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.